Jeff Landau
2022
In 2022, Jeff Landau earned a total compensation of $1.1M as Senior Vice President and Chief Business Officer at CytomX Therapeutics, a 40% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $183,350 |
|---|---|
| Option Awards | $376,233 |
| Salary | $393,333 |
| Stock Awards | $102,987 |
| Other | $5,000 |
| Total | $1,060,903 |
Landau received $393.3K in salary, accounting for 37% of the total pay in 2022.
Landau also received $183.4K in non-equity incentive plan, $376.2K in option awards, $103K in stock awards and $5K in other compensation.
Rankings
In 2022, Jeff Landau's compensation ranked 2,898th out of 5,753 executives tracked by ExecPay. In other words, Landau earned more than 49.6% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 2,898 out of 5,753 | 50th |
Division Manufacturing | 1,622 out of 3,133 | 48th |
Major group Chemicals And Allied Products | 754 out of 1,419 | 47th |
Industry group Drugs | 704 out of 1,320 | 47th |
Industry Pharmaceutical Preparations | 511 out of 966 | 47th |
Source: SEC filing on April 27, 2023.
Landau's colleagues
We found four more compensation records of executives who worked with Jeff Landau at CytomX Therapeutics in 2022.